Restless legs syndrome: pathophysiology and modern management

Area of Science:

• Neurology
• Sleep Medicine

Background:

• Restless legs syndrome (RLS) is a common neurological disorder impacting patient quality of life.
• It affects 5-25% of the general population, is more prevalent in women, and is common during pregnancy.

Purpose of the Study:

• To review and update treatment recommendations for Restless Legs Syndrome based on emerging evidence.
• To provide guidance on managing daily, intermittent, and refractory RLS, as well as RLS during pregnancy.

Main Methods:

• Literature review of recent evidence on RLS pathophysiology and treatment efficacy.
• Analysis of expert consensus on medication recommendations for different RLS types.

Main Results:

• Dopamine agonists (rotigotine, pramipexole, ropinirole) and gabapentinoids (gabapentin enacarbil, pregabalin, gabapentin) are effective for short-term RLS treatment.
• Recommended long-term treatments include rotigotine, gabapentin enacarbil, ropinirole, pramipexole, and gabapentin.
• Specific recommendations exist for daily, intermittent, and refractory RLS, with levodopa cautioned for daily use due to augmentation risk.
• Opioids and certain antiepileptics (carbamazepine, gabapentin) are considered safer in pregnancy.

Conclusions:

• Current evidence supports dopamine agonists and gabapentinoids as effective RLS treatments.
• Updated guidelines offer tailored approaches for various RLS presentations.
• While RLS may pose risks for metabolic and autonomic issues, it is not linked to increased cardiovascular complications.